Biomarker development in the precision medicine era: lung cancer as a case study. (Q38844239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

review article

1 reference

title

Biomarker development in the precision medicine era: lung cancer as a case study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

1 reference

Ashley J Vargas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Curtis C Harris

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

English

0 references

publication date

8 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

525-537

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

A new initiative on precision medicine

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Epidemiology. When an entire country is a cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Comprehensive molecular profiling of lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Phases of biomarker development for early detection of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

FDA perspective on companion diagnostics: an evolving paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Regulating laboratory-developed tests: devil will be in details

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Comprehensive genomic characterization of squamous cell lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Genetic polymorphisms in DNA repair genes and risk of lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Genetic variants and risk of lung cancer in never smokers: a genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Polymorphisms in XPD and TP53 and mutation in human lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Quantification of concentration and assessment of EGFR mutation in circulating DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Gene-expression profiles predict survival of patients with lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Diversity of gene expression in adenocarcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A five-gene signature and clinical outcome in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

From RNA-seq reads to differential expression results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Epigenetic biomarkers in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Long Noncoding RNAs in Cancer Pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Chromatin immunoprecipitation (ChIP) methodology and readouts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Application of microarrays for DNA methylation profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Proteomic patterns of tumour subsets in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Objective measurement and clinical significance of TILs in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Metabonomics: a platform for studying drug toxicity and gene function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Emerging applications of metabolomics in drug discovery and precision medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A metabolomic approach to lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Metabolic Signatures of Lung Cancer in Biofluids: NMR-Based Metabonomics of Urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The lung microbiome in moderate and severe chronic obstructive pulmonary disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A brave new world: the lung microbiota in an era of change

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Human pathogens abundant in the bacterial metagenome of cigarettes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The potential role of lung microbiota in lung cancer attributed to household coal burning exposures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Microbiome and Anticancer Immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Storage conditions of intestinal microbiota matter in metagenomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Processing faecal samples: a step forward for standards in microbial community analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

An expanded risk prediction model for lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A risk model for prediction of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

American Cancer Society lung cancer screening guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Self-reported Tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Lung carcinogenesis by tobacco smoke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Smoking, p53 mutation, and lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

p53: a frequent target for genetic abnormalities in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Statistical and practical considerations for clinical evaluation of predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Personalized medicine: Time for one-person trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Genome-wide Gene-Asbestos Exposure Interaction Association Study Identifies a Common Susceptibility Variant on 22q13.31 Associated with Lung Cancer Risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Passing messages between biological networks to refine predicted interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A novel approach for biomarker selection and the integration of repeated measures experiments from two assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Yeast Protein Interactome topology provides framework for coordinated-functionality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

International network of cancer genome projects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Understanding multicellular function and disease with human tissue-specific networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Dynamic modularity in protein interaction networks predicts breast cancer outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Commercialization of microfluidic point-of-care diagnostic devices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Design of the Women’s Health Initiative Clinical Trial and Observational Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Reporting recommendations for tumor marker prognostic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

REporting recommendations for tumour MARKer prognostic studies (REMARK)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Reporting recommendations for tumor marker prognostic studies (REMARK).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

REporting recommendations for tumour MARKer prognostic studies (REMARK).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The early detection research network: 10-year outlook

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Reduced lung-cancer mortality with low-dose computed tomographic screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Lung cancer screening poised to expand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Annual number of lung cancer deaths potentially avertable by screening in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma: A Comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classifi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Pulmonary nodules and CT screening: the past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Ten-year risk of false positive screening mammograms and clinical breast examinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Epidemiology of Lung Cancer*

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.56

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group

31 March 2020

1 reference

12 December 2020

EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer

1 reference

12 December 2020

Network-based drugs and biomarkers

1 reference

12 December 2020

Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests

1 reference

12 December 2020

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

12 December 2020

C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study)

1 reference

12 December 2020

Reporting recommendations for tumor marker prognostic studies (remark).

1 reference

12 December 2020

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27388699%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

PubMed publication ID

27388699

1 reference